Lilly shares safety data on next-gen obesity drug retatrutide; Revolution Medicines reports strong pancreatic cancer results

Lilly provided new data that detail the safety and tolerability profile of its next-generation obesity therapy, retatrutide. The information adds to the growing body of evidence supporting the drug's clinical development.

Revolution Medicines presented recent results for its experimental pancreatic cancer candidate, showing unprecedented response rates when combined with Tango Therapeutics as a co‑lead. The data suggest a potentially significant advance in treating this difficult disease.

The newsletter also flagged ongoing partnership activity, noting deals involving Roche and Johnson & Johnson, though specific terms were not disclosed.